N. Gaschignard

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study

Christian Pfister, Gwénaëlle Gravis, Aude Fléchon et al. · The Lancet Oncology · 2023 · 77 citations

Survival Endpoints, Surgical Oncology, Urology +7

Pathologic Findings in Radical Prostatectomy Specimens From Patients Eligible for Active Surveillance With Highly Selective Criteria: A Multicenter Study

Jean‐Baptiste Beauval, Guillaume Ploussard, M. Soulié et al. · Urology · 2012 · 67 citations

Urology, Surgical Oncology, Cancer Screening +8

Intermittent Androgen Suppression in the Treatment of Metastatic Prostate Cancer

Olivier Bouchot, L. Lenormand, Georges Karam et al. · European Urology · 2000 · 56 citations

Urology, Genitourinary Cancer, Medicine +5

Radical Prostatectomy for High-risk Prostate Cancer Defined by Preoperative Criteria: Oncologic Follow-up in National Multicenter Study in 813 Patients and Assessment of Easy-to-use Prognostic Substratification

Guillaume Ploussard, A. Masson-Lecomte, Jean‐Baptiste Beauval et al. · Urology · 2011 · 55 citations

Urology, Surgical Oncology, High-risk Prostate Cancer +8

Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study

Guillaume Ploussard, Frédéric Staerman, Jean Pierrevelcin et al. · World Journal of Urology · 2013 · 27 citations

Surgical Oncology, Urology, Salvage Radiotherapy +8